SAN DIEGO--(BUSINESS WIRE)--March 16, 2006--Hollis-Eden Pharmaceuticals, Inc. (Nasdaq:HEPH) today announced financial results for the fourth quarter and year ended December 31, 2005. For the fourth quarter, the Company reported a net loss of $10.4 million (or $0.50 per share), compared to a net loss of $8.4 million (or $0.44 per share) in the fourth quarter of 2004. For the full year, the Company reported a net loss of $29.4 million (or $1.46 per share), compared to a net loss of $24.8 million (or $1.28 per share) for full year 2004. Included in the fourth quarter and year-end 2005 loss was $3.0 million relating to the settlement of a dispute. Results for full-year 2005 and 2004 include $56,000 and $63,000, respectively, in revenue generated from funding of research and development expenses by Cystic Fibrosis Foundation Therapeutics, Inc. under the Company's collaboration agreement with the Foundation.
